ag-1296 has been researched along with Hypertension, Pulmonary in 1 studies
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, M | 1 |
| Donato, M | 1 |
| Guo, M | 1 |
| Wary, N | 1 |
| Miao, Y | 1 |
| Mao, S | 1 |
| Saito, T | 1 |
| Otsuki, S | 1 |
| Wang, L | 1 |
| Harper, RL | 1 |
| Sa, S | 1 |
| Khatri, P | 1 |
| Rabinovitch, M | 1 |
1 other study available for ag-1296 and Hypertension, Pulmonary
| Article | Year |
|---|---|
iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.
Topics: Animals; Cell Proliferation; Computer Simulation; Cyclic AMP Response Element-Binding Protein; Disea | 2021 |